We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Image of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne

Managing Editor

 at Technology Networks

As managing editor, Laura works with the associate editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.


Got a question for Laura Elizabeth Lansdowne?

Get in touch using the contact form linked here and we’ll get back to you shortly



Published Content
Total: 401
Improving Drug Discovery With Organoid-Based “Phase 0” Testing content piece image
Article

Improving Drug Discovery With Organoid-Based “Phase 0” Testing

Technology Networks recently had the pleasure of speaking with Soumita Das, associate professor at the University of California San Diego, to learn more about her work with organoids and some of the research activities at the HUMANOID™ Center of Research Excellence.
Exploring Human Biology and Disease With Organoid Models content piece image
Article

Exploring Human Biology and Disease With Organoid Models

Advances in cell culture techniques and stem cell technology have enabled the generation of organoids – three-dimensional aggregations of cells capable of recapitulating the structure and physiology of human organs in extraordinary detail. Technology Networks recently interviewed Soumita Das, associate professor at the University of California San Diego, to learn about the organoid models her team is developing.
Compound From Chinese Herb Exhibits Reversible Male Contraceptive Effects content piece image
News

Compound From Chinese Herb Exhibits Reversible Male Contraceptive Effects

Triptonide, a natural compound purified from the vine plant Tripterygium wilfordii Hook F, has been shown to possess reversible contraceptive effects in male mouse and primate models. The findings were published in Nature Communications.
CAR T Cells: A Living Targeted Drug, With Dr Matt Cooper content piece image
Video

CAR T Cells: A Living Targeted Drug, With Dr Matt Cooper

In this installment of Teach Me in 10, we're joined by Matt Cooper, co-founder and chief scientific officer at Wugen, Inc. He is also assistant professor of medicine at Washington University. Matt discusses what T cells are and how they can be engineered to recognize cancer cells.
Accelerating Scientific Study With Scalable Single-Cell Sequencing content piece image
Industry Insight

Accelerating Scientific Study With Scalable Single-Cell Sequencing

Technology Networks recently interviewed Alex Rosenberg, co-founder and CEO of Parse Biosciences to learn more about the company and its novel approach to single-cell sequencing.
Exploiting the Therapeutic Potential of Plants content piece image
Industry Insight

Exploiting the Therapeutic Potential of Plants

Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”.
180 Life Sciences: Developing Drugs To Tackle Distinct Inflammatory Diseases content piece image
Industry Insight

180 Life Sciences: Developing Drugs To Tackle Distinct Inflammatory Diseases

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.
Becoming a Science Writer content piece image
Video

Becoming a Science Writer

"How do I become a science writer?" is a common question that we get asked here at Technology Networks. That is why for this installment of Teach Me in 10, the guests are … well, us! We wanted to share stories of how we became science writers and communicators, highlighting some of the things that we have learned through our journeys and offering some top tips and tricks.
Cytisinicline: A Treatment To Help People Battling Nicotine Addiction content piece image
Industry Insight

Cytisinicline: A Treatment To Help People Battling Nicotine Addiction

The pharmaceutical company Achieve Life Sciences is focused on addressing one of the biggest public health threats globally – tobacco use. Technology Networks had the pleasure of speaking with the company's chief medical officer Cindy Jacobs, MD, PhD, to learn more about cytisinicline, a plant-based alkaloid the company is currently developing as a smoking cessation treatment.
Behind the World-First Export of Jamaican Psilocybin Mushrooms content piece image
Industry Insight

Behind the World-First Export of Jamaican Psilocybin Mushrooms

Mydecine Innovations Group recently announced that it had completed the first harvest and commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. We spoke with Mydecine’s chief scientific officer and co-founder, Rob Roscow, to find out more.
Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter